AUDREY FORKA: Open Payments
NPI 1780087213 · HAVRE DE GRACE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$923 in 41 payments from 15 companies in 2025. Trend: 2023 $716 · 2024 $1,175 · 2025 $923
Food & beverage: $923
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 7 | $198 |
| Supernus Pharmaceuticals, Inc. | 5 | $100 |
| ABBVIE INC. | 5 | $91 |
| Otsuka America Pharmaceutical, Inc. | 4 | $89 |
| Janssen Pharmaceuticals, Inc | 3 | $87 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Alkermes, Inc. | 3 | $55 |
| E.R. Squibb & Sons, L.L.C. | 2 | $53 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Collegium Pharmaceutical, Inc. | 2 | $37 |
Products named: INGREZZA, Qelbree, INVEGA SUSTENNA, VRAYLAR, ABILIFY MAINTENA, CAPLYTA, COBENFY, Auvelity.
Industry payments across MD — which companies pay providers there.
